Abstract
A causal relationship between exposure to smoking and increase in blood pressure (BP) is not yet clearly demonstrated. Some observations suggest a transient increase while smoking a cigarette or when exposed to passive smoking. Late stable hypertension may also occur as a consequence of smoking. This could be attributed to the progression of atherogenesis triggered by smoking (e.g. endothelial dysfunction). Endothelial dysfunction is strongly associated with hypertension. Impaired nitric oxide (NO) availability attributable to oxidative stress production, which causes NO breakdown, has also been considered as another mechanism. Smoking and hypertension seem to have an additive effect as risk factors for cardiovascular disease.
Keywords: Arterial wall, endothelium, hypertension, nitric oxide, risk factors, smoking, vascular damage, endothelial dysfunction, cardiovascular disease, atherosclerosis
Current Vascular Pharmacology
Title: Smoking and Hypertension: Independent or Additive Effects to Determining Vascular Damage?
Volume: 9 Issue: 5
Author(s): Aurelio Leone
Affiliation:
Keywords: Arterial wall, endothelium, hypertension, nitric oxide, risk factors, smoking, vascular damage, endothelial dysfunction, cardiovascular disease, atherosclerosis
Abstract: A causal relationship between exposure to smoking and increase in blood pressure (BP) is not yet clearly demonstrated. Some observations suggest a transient increase while smoking a cigarette or when exposed to passive smoking. Late stable hypertension may also occur as a consequence of smoking. This could be attributed to the progression of atherogenesis triggered by smoking (e.g. endothelial dysfunction). Endothelial dysfunction is strongly associated with hypertension. Impaired nitric oxide (NO) availability attributable to oxidative stress production, which causes NO breakdown, has also been considered as another mechanism. Smoking and hypertension seem to have an additive effect as risk factors for cardiovascular disease.
Export Options
About this article
Cite this article as:
Leone Aurelio, Smoking and Hypertension: Independent or Additive Effects to Determining Vascular Damage?, Current Vascular Pharmacology 2011; 9 (5) . https://dx.doi.org/10.2174/157016111796642706
DOI https://dx.doi.org/10.2174/157016111796642706 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Goto-kakizaki Rats: Its Suitability as Non-obese Diabetic Animal Model for Spontaneous Type 2 Diabetes Mellitus
Current Diabetes Reviews Biomedical Application of Polymers: A Case Study of Non-CNS Drugs Becoming CNS Acting Drugs
Central Nervous System Agents in Medicinal Chemistry The Economic Costs for the Control of Cardiovascular Risk: An Overview
Current Pharmaceutical Design Diagnostic use of Adenosine for Atrial Flutter with Regular Tachycardia
New Emirates Medical Journal Emerging Role of Complement in Ocular Diseases
Current Immunology Reviews (Discontinued) Outcomes of Perilla Seed Oil as an Additional Neuroprotective Therapy in Patients with Mild to Moderate Dementia: A Randomized Control Trial
Current Alzheimer Research Editorial [ Reducing Cardiovascular Risk: Is Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering Enough? ]
Current Vascular Pharmacology Catastrophic Antiphospholipid Syndrome - 20 Years Later
Current Rheumatology Reviews The Pharmacological Effects of Novokinin; a Designed Peptide Agonist of the Angiotensin AT<sab>2</sab> Receptor
Current Pharmaceutical Design The Role of local Insulin-like Growth Factor-1 Isoforms in the Pathophysiology of Skeletal Muscle
Current Genomics The Relationship between Age-Related Kidney Dysfunction and Framingham Risk Score in Healthy People in China
Current Aging Science Chronic Diseases and COVID-19: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Mechanism Aspect of ER Stress in Alzheimer's Disease: Current Approaches and Future Strategies
Current Drug Targets Probiotics as an Alternative Strategy for Prevention and Treatment of Human Diseases: A Review
Inflammation & Allergy - Drug Targets (Discontinued) Modification of Decoy Oligodeoxynucleotides to Achieve the Stability and Therapeutic Efficacy
Current Topics in Medicinal Chemistry Correlation of Salusin Beta with hs-CRP and ADMA in Hypertensive Children and Adolescents
Current Pharmaceutical Design Urine IL-18 is a Biomarker of Early Acute Kidney Injury (AKI)
Recent Patents on Biomarkers Significant Correlation between Cystatin C, Cerebral Infarction, and Potential Biomarker for Increased Risk of Stroke
Current Neurovascular Research Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Editorial (Oxidative Stress in the Vascular Wall: A Useful Physiological Process or a Therapeutic Target in Vascular Disease?)
Recent Patents on Cardiovascular Drug Discovery